LB Pharmaceuticals (LBRX)

• Market cap: $482M
• 1 day: -3.88%
• 5 days: -12.17%
• 1 month: 11.73%
• 3 months: 16.8%
• 6 months: 10.12%
• Year to date: 10.12%
• 1 year: 10.12%
• 5 years: 10.12%
• 10 years: 10.12%
• Sector: Healthcare
• Industry: Biotechnology

About: LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.